EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of TRPA1 as a Therapeutic Target in MYCN ‐Amplified Neuroblastoma

Alexandra Seger iD, Dora Adamič, Erick Muciño Olmos, Johannes Nilsson iD, Sofia Granados-Aparici, Isaac Vieco-Marti, Javanshir Esfandyari, Matilda Engström, Julia Martinez iD, Adriana Mañas iD, Samuel Navarro, Rosa Noguera und 2 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31875 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Alexandra Seger und 13 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pediatric Oncology, Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Neuroblastoma, TRPA1 Cation Channel, N-Myc Proto-Oncogene Protein, Gene Amplification. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Crafoordska Stiftelsen, Kungliga Fysiografiska Sällskapet i Lund, Barncancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuroblastoma (NB) is a childhood cancer with a high relapse rate despite intensive treatment. TRPA1 is a pain‐sensing ion channel with downstream impacts on proliferative and pro‐apoptotic pathways. Here, we evaluated TRPA1 expression in NB and performed pharmacological inhibition in preclinical models to assess its potential as a therapeutic target in NB.

Methods

TRPA1 protein levels were assessed in NB patient tumors on tissue microarrays. Bulk and single‐cell gene expression data were retrieved from publicly available databases. The effects of three TRPA1 inhibitors (AP‐18, A967079, and Bay 390) on NB cell viability and cell death were evaluated using NB patient‐derived xenograft (PDX)‐derived organoids. In vivo testing was performed in a MYCN ‐amplified NB PDX model. Drug combination testing was performed using combination or sequential treatments and evaluated using drug synergy scores.

Results

TRPA1 is widely expressed in NB patient tumors and preclinical patient‐derived NB models. Pharmacological TRPA1 inhibition decreased NB cell viability and increased cell death. In vivo TRPA1 inhibition alone did not significantly affect NB tumor growth. Pretreatment with TRPA1 inhibition prior to chemotherapy resulted in synergistic effects in vitro.

Conclusions

TRPA1 is expressed in NB tumors, and pharmacological TRPA1 inhibition can be effective in vitro and synergistic when used as pretreatment to chemotherapy. However, the tested inhibitors did not show in vivo efficacy, at least as monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaTRPA1 Cation ChannelN-Myc Proto-Oncogene ProteinGene AmplificationHumansAnimalsMiceXenograft Model Antitumor AssaysTumor Cells, CulturedCell ProliferationMice, SCIDMice, Inbred NOD

Stichwörter der Autor:innen

TRPA1chemotherapyneuroblastoma

Substanzen

TRPA1 Cation ChannelN-Myc Proto-Oncogene ProteinMYCN protein, humanTRPA1 protein, human

Autor:innen und Institutionen

  • Molecular Pediatric Oncology, Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.
  • Department of Pathology, Medical School, University of Valencia/Incliva/Ciberonc, Valencia, Spain.
  • Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy, IdiPAZ Research Center, University Hospital La Paz, Madrid, Spain.
  • Pediatric Onco-Hematology Clinical Unit IdiPAZ-CNIO, Spanish National Cancer Research Center (CNIO), Madrid, Spain.

ORCID-Profile: Alexandra Seger, Johannes Nilsson, Julia Martinez, Adriana Mañas, Kristina Aaltonen, Daniel Bexell

Förderung

  • Crafoordska Stiftelsen
  • Kungliga Fysiografiska Sällskapet i Lund
  • Barncancerfonden
  • Cancerfonden
  • Vetenskapsrådet

Zitieren

APA

Seger, A., Adamič, D., Olmos, E. M., Nilsson, J., Granados-Aparici, S., Vieco-Marti, I., Esfandyari, J., Engström, M., Martinez, J., Mañas, A., Navarro, S., Noguera, R., Aaltonen, K., & Bexell, D. (2025). Evaluation of TRPA1 as a Therapeutic Target in MYCN ‐Amplified Neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31875

Vancouver

Seger A, Adamič D, Olmos EM, Nilsson J, Granados-Aparici S, Vieco-Marti I, et al. Evaluation of TRPA1 as a Therapeutic Target in MYCN ‐Amplified Neuroblastoma. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31875

BibTeX
@article{Seger2025,
  author = {Seger, Alexandra and Adamič, Dora and Olmos, Erick Muciño and Nilsson, Johannes and Granados-Aparici, Sofia and Vieco-Marti, Isaac and Esfandyari, Javanshir and Engström, Matilda and Martinez, Julia and Mañas, Adriana and Navarro, Samuel and Noguera, Rosa and Aaltonen, Kristina and Bexell, Daniel},
  title = {Evaluation of TRPA1 as a Therapeutic Target in MYCN ‐Amplified Neuroblastoma},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31875}
}
Kostenlos starten →